Please assess the completion status of the following clinical trial:

Trial Title: The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with locally advanced, recurrent or metastatic histologically confirmed malignancy refractory to available standard treatment~Exclusion Criteria:~* Prior treatment with Lapatinib, Sorafenib or any agents targeting EGFR (other than trastuzumab), Raf, VEGF, or VEGFR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib and Sorafenib 1° level of dose (Type: EXPERIMENTAL): Lapatinib 750 mg/die + Sorafenib 200 mg bid
- Lapatinib and Sorafenib 2° level of dose (Type: EXPERIMENTAL): 2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
- Lapatinib and Sorafenib 3° level of dose (Type: EXPERIMENTAL): 3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
- Lapatinib and Sorafenib 4° level of dose (Type: EXPERIMENTAL): 4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).